Total Payments
$37,052
2024 Payments
$3,041
Companies
65
Transactions
938
Medicare Patients
2,589
Medicare Billing
$273,617
Payment Breakdown by Category
Consulting$18,229 (49.2%)
Food & Beverage$17,061 (46.0%)
Travel$1,386 (3.7%)
Education$376.46 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $18,229 | 11 | 49.2% |
| Food and Beverage | $17,061 | 904 | 46.0% |
| Travel and Lodging | $1,386 | 9 | 3.7% |
| Education | $376.46 | 14 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $5,342 | 31 | $0 (2024) |
| Incyte Corporation | $4,167 | 33 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,896 | 40 | $0 (2024) |
| Celgene Corporation | $2,861 | 54 | $0 (2024) |
| BeiGene USA, Inc. | $2,019 | 10 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $1,831 | 5 | $0 (2024) |
| ABBVIE INC. | $1,464 | 18 | $0 (2024) |
| Kite Pharma, Inc. | $1,447 | 6 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,355 | 80 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,184 | 73 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,041 | 146 | Daiichi Sankyo Inc. ($316.00) |
| 2023 | $8,330 | 158 | Incyte Corporation ($3,834) |
| 2022 | $4,927 | 133 | SERVIER PHARMACEUTICALS LLC ($1,760) |
| 2021 | $433.14 | 22 | Incyte Corporation ($64.51) |
| 2020 | $8,035 | 43 | AstraZeneca Pharmaceuticals LP ($2,602) |
| 2019 | $6,814 | 130 | GENZYME CORPORATION ($4,881) |
| 2018 | $2,717 | 145 | E.R. Squibb & Sons, L.L.C. ($445.99) |
| 2017 | $2,756 | 161 | Novartis Pharmaceuticals Corporation ($337.92) |
All Payment Transactions
938 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Oncology | ||||||
| 12/11/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/10/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $38.76 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $32.60 | General |
| Category: Hematology | ||||||
| 12/02/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $27.23 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: HEMATOLOGY | ||||||
| 11/21/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $16.84 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.56 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: Oncology | ||||||
| 11/12/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Oncology | ||||||
| 11/05/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $33.69 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: Oncology | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Oncology | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: BioOncology | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $14.81 | General |
| 10/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $31.18 | General |
| Category: Hematology | ||||||
| 10/15/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 538 | 1,022 | $119,506 | $64,186 |
| 2022 | 5 | 579 | 1,088 | $131,325 | $67,526 |
| 2021 | 6 | 746 | 1,289 | $141,764 | $80,812 |
| 2020 | 6 | 726 | 1,256 | $125,085 | $61,094 |
Total Patients
2,589
Total Services
4,655
Medicare Billing
$273,617
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 116 | 297 | $40,302 | $20,501 | 50.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 177 | $24,054 | $12,021 | 50.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 151 | 243 | $18,242 | $11,149 | 61.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 109 | 187 | $14,070 | $7,948 | 56.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 65 | $12,585 | $6,913 | 54.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 34 | 53 | $10,253 | $5,653 | 55.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 128 | 325 | $42,026 | $21,768 | 51.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 98 | 215 | $27,754 | $14,332 | 51.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 160 | 260 | $18,166 | $11,167 | 61.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 55 | 63 | $11,859 | $6,662 | 56.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 87 | 141 | $9,868 | $6,167 | 62.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 31 | $5,723 | $3,473 | 60.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 39 | $11,925 | $3,046 | 25.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 14 | 14 | $4,004 | $910.44 | 22.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 129 | 293 | $36,232 | $21,085 | 58.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 236 | 399 | $24,588 | $17,373 | 70.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 91 | 190 | $23,486 | $13,643 | 58.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 97 | 105 | $18,318 | $10,453 | 57.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 105 | 174 | $10,974 | $7,410 | 67.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 58 | $10,124 | $6,006 | 59.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 22 | 27 | $7,262 | $1,952 | 26.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 23 | $6,700 | $1,775 | 26.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 20 | $4,080 | $1,116 | 27.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 242 | 447 | $26,187 | $15,013 | 57.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 131 | 260 | $30,532 | $14,872 | 48.7% |
About Dr. Asim Pati, MD
Dr. Asim Pati, MD is a Hematology healthcare provider based in Spartanburg, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1841294121.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Asim Pati, MD has received a total of $37,052 in payments from pharmaceutical and medical device companies, with $3,041 received in 2024. These payments were reported across 938 transactions from 65 companies. The most common payment nature is "Consulting Fee" ($18,229).
As a Medicare-enrolled provider, Pati has provided services to 2,589 Medicare beneficiaries, totaling 4,655 services with total Medicare billing of $273,617. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Location Spartanburg, SC
- Active Since 06/02/2005
- Last Updated 12/01/2020
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1841294121
Products in Payments
- CD38 (Drug) $4,374
- CALQUENCE (Drug) $3,448
- BRUKINSA (Drug) $2,469
- Rituxan (Drug) $1,800
- TIBSOVO (Drug) $1,760
- Yescarta (Drug) $1,396
- VENCLEXTA (Drug) $1,280
- OPDIVO (Biological) $823.45
- Lenvima (Drug) $724.08
- IMBRUVICA (Drug) $627.76
- KEYTRUDA (Biological) $478.04
- DARZALEX (Biological) $428.93
- TASIGNA (Drug) $360.38
- REBLOZYL (Biological) $340.12
- Pomalyst (Drug) $326.65
- XOSPATA (Drug) $291.70
- Enhertu (Drug) $246.12
- IBRANCE (Drug) $233.68
- JEVTANA (Drug) $229.76
- TAGRISSO (Drug) $226.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.